Dicerna Pharmaceuticals Inc
DRNA
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.97B
Close$
$39.91
4.4% upside
Current Fair Value
4.4% upsideUndervalued by 4.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.97 Billion |
|---|---|
| Enterprise Value | $3.06 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.51 |
| Beta | 0.79 |
| Outstanding Shares | 77,747,134 |
Return
| Return on Equity | -115.58% |
|---|---|
| Return on Assets | -16.12% |
| Return on Invested Capital | -23.10% |
Valuation & Multiples
| P/E Ratio | -25.31 |
|---|---|
| PEG | 115.77 |
| Price to Sales | 19.11 |
| Price to Book Ratio | 38.22 |
| Enterprise Value to Revenue | 15.88 |
| Enterprise Value to EBIT | -24.88 |
| Enterprise Value to Net Income | -25 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 2.38 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Dicerna Pharmaceuticals Inc
CEO: Douglas Fambrough